
Emerging non-genetic approaches that offer innovative treatment and palliation in sickle cell disease (SCD)

RBC intrinsic targets

- HbS polymerization through HbF induction
- HbS polymerization through sRBC hydration
- Other anti-sickling agents
- Intracellular sRBC oxidative changes (antioxidant therapy)



RBC extrinsic targets

- Abnormal cellular adhesion and vascular dysfunction
- · Platelet activation and hypercoagulability
- Leukocytes, cytokines, and other inflammatory mediators



Risk-Benefit assessments for emerging non-genetic therapies in SCD

